InterSystems HealthShare® Unified Care Record and TrakCare® garner continued recognition CAMBRIDGE, Mass.–(BUSINESS WIRE)–InterSystems, a creative…
SEATTLE–(BUSINESS WIRE)–Intelus today announced it has joined NVIDIA Inception, a program designed to nurture startups…
Collaboration accelerates development of artificial intelligence-enabled air interfaces SANTA ROSA, Calif.–(BUSINESS WIRE)–$KEYS #5GNR–Keysight Technologies, Inc….
CHICAGO–(BUSINESS WIRE)–The Claro Group (“Claro”) has bolstered its Midwest presence with the addition of Kate…
Company’s upgraded freemium tier helps organizations jump-start their Continuous Compromise Assessment journey to simplify their…
MAINZ, Germany, February 15, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will…
LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New…
STAT-201 is being developed as a novel, immune-modulation therapy for treating Crohn’s Disease Phase 3 trial…
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and…
Quarter Saw Large Increases Quarter Over Same Quarter Gross Profit and Revenue Gains LAS VEGAS,…
BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical…
Frank Stonebanks Headshot Frank Stonebanks, CEO, Renibus Therapeutics Founder, CEO and healthcare venture capitalist, Stonebanks…
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
MONTREAL, Feb. 15, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the…
Conference Call on Tuesday, March 1, 2022 at 8:30 a.m. ET LEXINGTON, Mass., Feb. 15,…
Double-Blind, Peer-Reviewed Study Published in World Journal of Advanced Research and Reviews UBN RELIEF™ UBN…
Expands Clinical Operations Team in Advance of Pivotal Clinical Studies CARLSBAD, Calif., Feb. 15, 2022…
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US…
Highlights Potential of PRL-02 as Best-in-Class, Next-Generation Androgen Biosynthesis Inhibitor for Treatment of Advanced Prostate…